Bionano Genomics (NASDAQ:BNGO) Announces Earnings Results

Bionano Genomics (NASDAQ:BNGO) announced its earnings results on Wednesday. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.88) by $0.12, reports. Bionano Genomics had a negative return on equity of 56.22% and a negative net margin of 92.59%.The company had revenue of $6.69 million for the quarter, compared to analysts’ expectations of $6.57 million.

Here are the key takeaways from Bionano Genomics’ conference call:

• Revenue came in at $6.7 million in Q1 2026, up 4% year over year and at the high end of guidance, while flow cell sales hit a record first-quarter level of 8,178 units.
• Consumable revenue rose 20% year over year to $3.9 million, reflecting stronger usage from existing customers and a shift toward more recurring revenue.
• The company highlighted major reimbursement wins for OGM, including a 47% increase in the payment determination for hematologic malignancies and a new category 1 CPT code for constitutional genetic disorders.
• Adjusted gross margin improved to 49% in Q1 from 46% a year ago, and management said the company expects its cash runway to extend into 2027.
• Management said Bionano does not expect to reach operating cash flow break-even by the end of 2026, though it aims to reduce burn further by Q4 2027.

Bionano Genomics Trading Down 2.4%

Shares of BNGO stock traded down $0.03 on Thursday, reaching $1.22. The company had a trading volume of 206,732 shares, compared to its average volume of 284,545. The company has a current ratio of 1.98, a quick ratio of 1.74 and a debt-to-equity ratio of 0.08. The stock has a market cap of $13.53 million, a PE ratio of -0.26 and a beta of 1.62. The company has a 50-day moving average of $1.19 and a 200-day moving average of $1.40. Bionano Genomics has a 12 month low of $1.06 and a 12 month high of $5.50.

Wall Street Analysts Forecast Growth

BNGO has been the topic of a number of research analyst reports. HC Wainwright decreased their price objective on shares of Bionano Genomics from $7.00 to $6.00 and set a “buy” rating on the stock in a report on Monday, April 13th. Weiss Ratings upgraded shares of Bionano Genomics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $6.00.

Hedge Funds Weigh In On Bionano Genomics

Institutional investors and hedge funds have recently modified their holdings of the business. Carret Asset Management LLC grew its position in shares of Bionano Genomics by 76.4% in the 4th quarter. Carret Asset Management LLC now owns 44,100 shares of the company’s stock valued at $67,000 after purchasing an additional 19,100 shares during the period. DRW Securities LLC acquired a new position in shares of Bionano Genomics in the 4th quarter valued at approximately $258,000. Geode Capital Management LLC grew its position in shares of Bionano Genomics by 148.8% in the 4th quarter. Geode Capital Management LLC now owns 66,766 shares of the company’s stock valued at $102,000 after purchasing an additional 39,928 shares during the period. Renaissance Technologies LLC acquired a new position in shares of Bionano Genomics in the 4th quarter valued at approximately $57,000. Finally, Jane Street Group LLC acquired a new position in shares of Bionano Genomics in the 4th quarter valued at approximately $34,000. 11.35% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Bionano Genomics

Here are the key news stories impacting Bionano Genomics this week:

• Positive Sentiment: Bionano reported Q1 2026 EPS of ($0.76), better than the expected ($0.88), and revenue of $6.69 million, which also beat estimates. Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates
• Positive Sentiment: Management said the business is seeing continued engagement from its installed base, with positive utilization trends in its OGM and VIA software communities, and highlighted record flow cell sales. Bionano Reports First Quarter 2026 Results and Provides a Business Update
• Neutral Sentiment: The company issued second-quarter revenue guidance of $7.5 million to $7.8 million, roughly in line with expectations, which suggests steady near-term sales but no major upside surprise yet. Bionano Reports First Quarter 2026 Results and Provides a Business Update
• Negative Sentiment: Despite the earnings beat, Bionano is still posting steep losses, with a negative net margin and negative return on equity, and the latest coverage points to supply constraints and leadership transitions as added risks. Bionano Genomics Inc (BNGO) Q1 2026 Earnings Call Highlights: Record Flow Cell Sales and …
• Negative Sentiment: Analysts’ attention is now shifting to the Q4 2026 earnings preview, keeping the stock under scrutiny as investors wait for confirmation that revenue growth can continue. Bionano Genomics Q4 2026 earnings preview

Bionano Genomics Company Profile

Bionano Genomics, Inc (NASDAQ: BNGO) develops and commercializes high‐resolution genome analysis tools designed to map structural variants and large‐scale genomic rearrangements. At the core of its technology is the Saphyr® optical genome mapping system, which uses nanochannel arrays to linearize megabase‐length DNA molecules, proprietary fluorescent labeling reagents to highlight specific sequence motifs, and advanced image processing software to detect structural changes with high sensitivity.